iBio (IBIO) Research Hub

iBio (IBIO) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 0.707 USD (-1.50%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.40, market cap 0.02B. This hub links to the full technical, earnings and options research available for IBIO.

Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close0.707 USD (-1.50%)
52-week range0.6859 USD – 1.77 USD
Trend regimeRange
14-day RSI20 (Oversold)
Trailing P/E-2.40
Market cap0.02B
Dividend yield0.00%
Next earnings2026-09-04

Available research for IBIO

Earnings

IBIO earnings date and last-quarter result: next report 2026-09-04, last quarter miss, P/E -2.40. Updated 2026-07-23.

Options: Covered Call

Covered Call on IBIO: how it works, illustrative setup around the real 0.707 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on IBIO: how it works, illustrative setup around the real 0.707 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on IBIO: how it works, illustrative setup around the real 0.707 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

IBIO technical analysis: range, last 0.707 USD, RSI 20, 52w range 0.6859 USD–1.77 USD, real support/resistance. Updated 2026-10-26.

More on SniperIQ

Frequently asked questions

What sector is IBIO in?

iBio (IBIO) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is IBIO in an uptrend or downtrend?

As of 2026-10-26, IBIO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is IBIO's trailing P/E ratio?

IBIO's trailing P/E is -2.40, with a market cap of 0.02B. See the earnings research page for full valuation detail.

When does IBIO next report earnings?

IBIO is next scheduled to report earnings on 2026-09-04.